Patient-Controlled Analgesia: The Importance of Effector Site Pharmacokinetics

Chapter

Abstract

Opioid transit across the blood-brain barrier (BBB) and into the central nervous system (CNS) is complex and is dependent on a drug’s specific physiochemical properties, such as lipophilicity, molecular size, degree of protein binding and ionization, as well as physiological factors, such as metabolism and drug clearance. More recently, drug equilibration from the systemic circulation to the CNS has been determined to be significantly governed by a dynamic interplay between influx and efflux membrane transporter pumps and synergy between transporters and metabolizing enzymes. In combination with physicochemical and physiological factors, these transporter systems regulate CNS opioid receptor exposure and effectively determine analgesic onset, as well as the magnitude and duration of pharmacodynamic (PD) effects, including side effects. The infamous and colorful bank robber “Slick Willie” Sutton suggested that the reason he robbed banks was “because that’s where they keep the money”. Following Sutton’s lead, we should look to the CNS, not traditional venous pharmacokinetic (PK) parameters, to better understand and more appropriately select opioids and routes of administration for various clinical use scenarios.

References

  1. 1.
    Willie Sutton. the source for all the notorious details. http://williesutton.com/index.html. Accessed 16 Aug 2012.
  2. 2.
    Smith H. The metabolism of opioid agents and the clinical impact of their active metabolites. Clin J Pain. 2011;27:824–38.PubMedCrossRefGoogle Scholar
  3. 3.
    Girardun F. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Dialogues Clin Neurosci. 2006;8:311–21.Google Scholar
  4. 4.
    Redzic Z. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS. 2011;8(3):1–23. Available at http://www.fluidsbarrierscns.com/content/8/1/3.Google Scholar
  5. 5.
    Sharom FJ, DiDiodado G, Yu X, Ashbourne JD. Interaction of the P-glycoprotein multidrug transporter with peptides and ionophores. J Biol Chem. 1995;270:10334–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Wandel C, Kim R, Wood M, Wood A. Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology. 2002;96:913–20.PubMedCrossRefGoogle Scholar
  7. 7.
    Huwyler J, Drewe J, Klusemann C, Fricker G. Evidence for P-glycoprotein-modulated penetration of morphine and morphine-6-glucuronide into brain capillary endothelium. Brit J Pharmacol. 1996;118:1879–85.CrossRefGoogle Scholar
  8. 8.
    Lorenzini KI, Daali Y, Dayer P, Desmeules J. Pharmacokinetic-pharmacodynamic modelling of opioids in healthy human volunteers. A minireview. Basic Clin Pharmacol Toxicol. 2012;110:219–26.CrossRefGoogle Scholar
  9. 9.
    Lötsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manag. 2005;29(5 Suppl):S90–103.CrossRefGoogle Scholar
  10. 10.
    Shafer SL, Flood PD. The pharmacology of opioids in geriatric patients. In: Silverstein JH, Rooke GE, Reves JG, McLeskey CH, editors. Geriatric anesthesiology. New York: Springer Science; 2007. p. 209.Google Scholar
  11. 11.
    Scott JC, Cooke JE, Stanski DR. Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. Anesthesiology. 1991;74:34–42.PubMedCrossRefGoogle Scholar
  12. 12.
    Barietta JF. Clinical and economic burden of opioid use for postsurgical pain: focus on ventilatory impairment and ileus. Pharmacotherapy. 2012;32(9 Pt 2):12S–8.CrossRefGoogle Scholar
  13. 13.
    Oderda GM, Evans RS, Lloyd J, et al. Cost of opioid-related adverse drug events in surgical patients. J Pain Symptom Manag. 2003;25:276–83.CrossRefGoogle Scholar
  14. 14.
    Scholz J, Steinfath M, Schultz M. Clinical pharmacokinetics of alfentanil, fentanyl, and sufentanil. Clin Pharmacother. 1996;31:275–92.CrossRefGoogle Scholar
  15. 15.
    Gan TJ, Palmer PP, Royal M. Optimizing a drug for PCA delivery: the clinical importance of CST1/2 and t1/2ke0. Poster A1298 presented at the Annual Meeting of the American Society of Anesthesiologists, October 12, 2013, San Francisco, CA. http://www.asaabstracts.com. Accessed 04 Jun 2014.
  16. 16.
    Melson T, Boyer DL, Minkowitz H, Palmer PP, Royal M. Sufentanil NanoTab PCA System versus IV PCA morphine for postoperative pain: a randomized, open-label, active-comparator trial. Poster A3087 presented at the Annual Meeting of the American Society of Anesthesiologists, October 14, 2013, San Francisco, CA. http://www.asaabstracts.com. Accessed 04 Jun 2014.
  17. 17.
    Mather LE. Opioids: a pharmacologist’s delight! Clin Exp Pharmacol Physiol. 1995;22:833–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Warfield CA, Kahn CH. Acute pain management: programs in US hospitals and experiences and attitudes among US adults. Anesthesiology. 1995;83:1090–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003;97:534–40.PubMedCrossRefGoogle Scholar
  20. 20.
    McGrath B, Elgendy H, Chung F, et al. Thirty percent of patients have moderate to severe pain 24 h after ambulatory surgery: a survey of 5,703 patients. Can J Anesth. 2004;51:886–91.PubMedCrossRefGoogle Scholar
  21. 21.
    Rawal N, Hylander J, Nydahl PA, et al. Survey of postoperative analgesia following ambulatory surgery. Acta Anaesth Scand. 1997;41:1017–22.PubMedCrossRefGoogle Scholar
  22. 22.
    Constantini R, Affaitati G, Fabrizio A, Giamberardino MA. Controlling pain in the post-operative setting.et al. Int J Clin Pharmacol Ther. 2011;49:116–27.CrossRefGoogle Scholar
  23. 23.
    Sinatra R. Causes and consequences of inadequate management of acute pain. Pain Med. 2010;11:1859–71.PubMedCrossRefGoogle Scholar
  24. 24.
    US Department of Health and Human Services, Centers for Medicare and Medicaid. HCAHPS: Patients’ perspectives of care survey. http://www.cms.gov/HospitalQualityInits/30_HospitalHCAHPS.asp. Accessed 13 Aug 2012.
  25. 25.
    Ballantyne JC, Carr DB, Chalmers TC, et al. Postoperative patient-controlled analgesia: meta-analyses of initial randomized controlled trials. J Clin Anesth. 1993;5:182–93.PubMedCrossRefGoogle Scholar
  26. 26.
    Hudcova J, McNicol ED, Quah CS, et al. Patient controlled opioid analgesia versus conventional opioid analgesia for postoperative pain, Cochrane Database Syst Rev. 2006;(4):CD003348. doi:10.1002/14651858. CD003348.pub2.

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.AcelRx Pharmaceuticals, IncRedwood CityUSA

Personalised recommendations